CanSino Biologics Inc. (CASBF)
OTCMKTS
· Delayed Price · Currency is USD
3.200
-1.400 (-30.43%)
At close: Apr 9, 2025
CanSino Biologics Employees
CanSino Biologics had 1,494 employees as of December 31, 2023. The number of employees decreased by 797 or -34.79% compared to the previous year.
Employees
1,494
Change (1Y)
-797
Growth (1Y)
-34.79%
Revenue / Employee
$77,611
Profits / Employee
-$34,745
Market Cap
1.37B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 3,116 |
Glass House Brands | 374 |
Northwest Biotherapeutics | 25 |
Elite Pharmaceuticals | 64 |
CytoDyn | 9 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Longduoduo Company | 49 |
CanSino Biologics News
- 2 years ago - Riding Covid Vaccine Highs, CanSino Plans Swiss Listing - Seeking Alpha
- 2 years ago - World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China. - Business Wire
- 2 years ago - China's CanSinoBIO H1 revenue drops on weaker COVID shot demand - Reuters
- 3 years ago - CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing - PRNewsWire
- 3 years ago - CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research - PRNewsWire
- 3 years ago - CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - PRNewsWire
- 3 years ago - CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia - PRNewsWire
- 3 years ago - Latest Study Shows Advantages of CanSinoBIO's Convidecia™ as Heterologous Booster against Omicron Variant - PRNewsWire